Adjunctive	O
aripiprazole	B:C0299792
in	O
risperidone	O
-	O
induced	O
hyperprolactinaemia	O
:	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
trial	I:C1706408
Hyperprolactinaemia	O
is	O
a	O
troublesome	O
side	O
-	I:C0879626
effect	I:C0879626
of	O
treatment	O
with	O
antipsychotics	O
.	O

Adjunctive	O
aripiprazole	O
in	O
risperidone	B:C0073393
-	O
induced	O
hyperprolactinaemia	O
:	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
trial	I:C1706408
Hyperprolactinaemia	O
is	O
a	O
troublesome	O
side	O
-	I:C0879626
effect	I:C0879626
of	O
treatment	O
with	O
antipsychotics	O
.	O

Adjunctive	O
aripiprazole	O
in	O
risperidone	O
-	O
induced	O
hyperprolactinaemia	B:C0020514
:	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
trial	I:C1706408
Hyperprolactinaemia	O
is	O
a	O
troublesome	O
side	O
-	I:C0879626
effect	I:C0879626
of	O
treatment	O
with	O
antipsychotics	O
.	O

Adjunctive	O
aripiprazole	O
in	O
risperidone	O
-	O
induced	O
hyperprolactinaemia	O
:	O
double	B:C0013072
-	I:C0013072
blind	I:C0013072
,	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
trial	I:C1706408
Hyperprolactinaemia	O
is	O
a	O
troublesome	O
side	O
-	I:C0879626
effect	I:C0879626
of	O
treatment	O
with	O
antipsychotics	O
.	O

Adjunctive	O
aripiprazole	O
in	O
risperidone	O
-	O
induced	O
hyperprolactinaemia	O
:	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
randomised	B:C0282440
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
trial	I:C1706408
Hyperprolactinaemia	O
is	O
a	O
troublesome	O
side	O
-	I:C0879626
effect	I:C0879626
of	O
treatment	O
with	O
antipsychotics	O
.	O

Adjunctive	O
aripiprazole	O
in	O
risperidone	O
-	O
induced	O
hyperprolactinaemia	O
:	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
randomised	O
,	O
placebo	B:C1706408
-	I:C1706408
controlled	I:C1706408
trial	I:C1706408
Hyperprolactinaemia	O
is	O
a	O
troublesome	O
side	O
-	I:C0879626
effect	I:C0879626
of	O
treatment	O
with	O
antipsychotics	O
.	O

Adjunctive	O
aripiprazole	O
in	O
risperidone	O
-	O
induced	O
hyperprolactinaemia	O
:	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
trial	I:C1706408
Hyperprolactinaemia	B:C0020514
is	O
a	O
troublesome	O
side	O
-	I:C0879626
effect	I:C0879626
of	O
treatment	O
with	O
antipsychotics	O
.	O

Adjunctive	O
aripiprazole	O
in	O
risperidone	O
-	O
induced	O
hyperprolactinaemia	O
:	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
trial	I:C1706408
Hyperprolactinaemia	O
is	O
a	O
troublesome	O
side	B:C0879626
-	I:C0879626
effect	I:C0879626
of	O
treatment	O
with	O
antipsychotics	O
.	O

Adjunctive	O
aripiprazole	O
in	O
risperidone	O
-	O
induced	O
hyperprolactinaemia	O
:	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
trial	I:C1706408
Hyperprolactinaemia	O
is	O
a	O
troublesome	O
side	O
-	I:C0879626
effect	I:C0879626
of	O
treatment	B:C0087111
with	O
antipsychotics	O
.	O

Adjunctive	O
aripiprazole	O
in	O
risperidone	O
-	O
induced	O
hyperprolactinaemia	O
:	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
randomised	O
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
trial	I:C1706408
Hyperprolactinaemia	O
is	O
a	O
troublesome	O
side	O
-	I:C0879626
effect	I:C0879626
of	O
treatment	O
with	O
antipsychotics	B:C0040615
.	O

This	O
double	B:C0013072
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
study	I:C1706408
aimed	O
at	O
examining	O
the	O
effect	O
of	O
adjunctive	O
treatment	O
with	O
10	O
mg	O
aripiprazole	O
on	O
prolactin	O
levels	I:C0373706
and	O
sexual	O
side	O
-	I:C0879626
effects	I:C0879626
in	O
patients	O
with	O
schizophrenia	O
symptomatically	O
maintained	O
on	O
risperidone	O
.	O

This	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	B:C1706408
-	I:C1706408
controlled	I:C1706408
study	I:C1706408
aimed	O
at	O
examining	O
the	O
effect	O
of	O
adjunctive	O
treatment	O
with	O
10	O
mg	O
aripiprazole	O
on	O
prolactin	O
levels	I:C0373706
and	O
sexual	O
side	O
-	I:C0879626
effects	I:C0879626
in	O
patients	O
with	O
schizophrenia	O
symptomatically	O
maintained	O
on	O
risperidone	O
.	O

This	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
study	I:C1706408
aimed	O
at	O
examining	O
the	O
effect	O
of	O
adjunctive	O
treatment	O
with	O
10	O
mg	O
aripiprazole	O
on	O
prolactin	B:C0373706
levels	I:C0373706
and	O
sexual	O
side	O
-	I:C0879626
effects	I:C0879626
in	O
patients	O
with	O
schizophrenia	O
symptomatically	O
maintained	O
on	O
risperidone	O
.	O

This	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
study	I:C1706408
aimed	O
at	O
examining	O
the	O
effect	O
of	O
adjunctive	O
treatment	O
with	O
10	O
mg	O
aripiprazole	O
on	O
prolactin	O
levels	I:C0373706
and	O
sexual	O
side	B:C0879626
-	I:C0879626
effects	I:C0879626
in	O
patients	O
with	O
schizophrenia	O
symptomatically	O
maintained	O
on	O
risperidone	O
.	O

This	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
study	I:C1706408
aimed	O
at	O
examining	O
the	O
effect	O
of	O
adjunctive	O
treatment	O
with	O
10	O
mg	O
aripiprazole	O
on	O
prolactin	O
levels	I:C0373706
and	O
sexual	O
side	O
-	I:C0879626
effects	I:C0879626
in	O
patients	O
with	O
schizophrenia	B:C0036341
symptomatically	O
maintained	O
on	O
risperidone	O
.	O

This	O
double	O
-	I:C0013072
blind	I:C0013072
,	O
placebo	O
-	I:C1706408
controlled	I:C1706408
study	I:C1706408
aimed	O
at	O
examining	O
the	O
effect	O
of	O
adjunctive	O
treatment	O
with	O
10	O
mg	O
aripiprazole	O
on	O
prolactin	O
levels	I:C0373706
and	O
sexual	O
side	O
-	I:C0879626
effects	I:C0879626
in	O
patients	O
with	O
schizophrenia	O
symptomatically	O
maintained	O
on	O
risperidone	B:C0073393
.	O

Thirty	O
patients	O
taking	O
risperidone	B:C0073393
were	O
enrolled	O
into	O
the	O
trial	O
(	O
CTRI	O
/	O
2012/11/003114	O
)	O
.	O

Thirty	O
patients	O
taking	O
risperidone	O
were	O
enrolled	O
into	O
the	O
trial	B:C0008976
(	O
CTRI	O
/	O
2012/11/003114	O
)	O
.	O

Aripiprazole	B:C0299792
was	O
administered	O
at	O
a	O
fixed	O
daily	O
dose	O
of	O
10	O
mg	O
/	O
day	O
for	O
8	O
weeks	O
.	O

Aripiprazole	O
was	O
administered	B:C0806914
at	O
a	O
fixed	O
daily	O
dose	O
of	O
10	O
mg	O
/	O
day	O
for	O
8	O
weeks	O
.	O

Serum	B:C1277972
prolactin	I:C1277972
was	O
measured	O
at	O
baseline	O
and	O
at	O
8	O
weeks	O
.	O

Hyperprolactinaemia	B:C0020514
-	O
related	O
problems	O
,	O
psychopathology	O
and	O
side	O
-	I:C0879626
effects	I:C0879626
were	O
evaluated	O
every	O
2	O
weeks	O
.	O

Hyperprolactinaemia	O
-	O
related	O
problems	B:C0033213
,	O
psychopathology	O
and	O
side	O
-	I:C0879626
effects	I:C0879626
were	O
evaluated	O
every	O
2	O
weeks	O
.	O

Hyperprolactinaemia	O
-	O
related	O
problems	O
,	O
psychopathology	B:C0004936
and	O
side	O
-	I:C0879626
effects	I:C0879626
were	O
evaluated	O
every	O
2	O
weeks	O
.	O

Hyperprolactinaemia	O
-	O
related	O
problems	O
,	O
psychopathology	O
and	O
side	B:C0879626
-	I:C0879626
effects	I:C0879626
were	O
evaluated	O
every	O
2	O
weeks	O
.	O

Hyperprolactinaemia	O
-	O
related	O
problems	O
,	O
psychopathology	O
and	O
side	O
-	I:C0879626
effects	I:C0879626
were	O
evaluated	B:C0220825
every	O
2	O
weeks	O
.	O

Prolactin	B:C0857016
levels	I:C0857016
decreased	I:C0857016
by	O
58	O
%	O
in	O
the	O
aripiprazole	O
group	O
compared	O
with	O
an	O
increase	O
by	O
22	O
%	O
in	O
the	O
placebo	O
group	O
.	O

Prolactin	O
levels	I:C0857016
decreased	I:C0857016
by	O
58	O
%	O
in	O
the	O
aripiprazole	B:C0299792
group	O
compared	O
with	O
an	O
increase	O
by	O
22	O
%	O
in	O
the	O
placebo	O
group	O
.	O

Prolactin	B:C0580441
levels	I:C0580441
normalised	I:C0580441
in	O
46	O
%	O
of	O
patients	O
in	O
the	O
aripiprazole	O
group	O
(	O
number	O
needed	O
to	O
treat	O
,	O
NNT=2	O
)	O
.	O

Prolactin	O
levels	I:C0580441
normalised	I:C0580441
in	O
46	O
%	O
of	O
patients	O
in	O
the	O
aripiprazole	B:C0299792
group	O
(	O
number	O
needed	O
to	O
treat	O
,	O
NNT=2	O
)	O
.	O

Aripiprazole	B:C0299792
improved	O
erectile	O
dysfunction	I:C0242350
in	O
five	O
out	O
of	O
six	O
patients	O
.	O

Aripiprazole	O
improved	B:C0184511
erectile	O
dysfunction	I:C0242350
in	O
five	O
out	O
of	O
six	O
patients	O
.	O

Aripiprazole	O
improved	O
erectile	B:C0242350
dysfunction	I:C0242350
in	O
five	O
out	O
of	O
six	O
patients	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
change	O
in	O
psychopathology	B:C0004936
or	O
side	O
-	I:C0879626
effects	I:C0879626
between	O
groups	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
change	O
in	O
psychopathology	O
or	O
side	B:C0879626
-	I:C0879626
effects	I:C0879626
between	O
groups	O
.	O

Adjunctive	O
aripiprazole	B:C0299792
reduced	O
prolactin	O
levels	I:C0373706
in	O
those	O
treated	O
with	I:C0332293
risperidone	O
,	O
with	O
no	O
effect	O
on	O
psychopathology	O
and	O
extrapyramidal	O
symptoms	I:C0234133
.	O

Adjunctive	O
aripiprazole	O
reduced	O
prolactin	B:C0373706
levels	I:C0373706
in	O
those	O
treated	O
with	I:C0332293
risperidone	O
,	O
with	O
no	O
effect	O
on	O
psychopathology	O
and	O
extrapyramidal	O
symptoms	I:C0234133
.	O

Adjunctive	O
aripiprazole	O
reduced	O
prolactin	O
levels	I:C0373706
in	O
those	O
treated	B:C0332293
with	I:C0332293
risperidone	O
,	O
with	O
no	O
effect	O
on	O
psychopathology	O
and	O
extrapyramidal	O
symptoms	I:C0234133
.	O

Adjunctive	O
aripiprazole	O
reduced	O
prolactin	O
levels	I:C0373706
in	O
those	O
treated	O
with	I:C0332293
risperidone	B:C0073393
,	O
with	O
no	O
effect	O
on	O
psychopathology	O
and	O
extrapyramidal	O
symptoms	I:C0234133
.	O

Adjunctive	O
aripiprazole	O
reduced	O
prolactin	O
levels	I:C0373706
in	O
those	O
treated	O
with	I:C0332293
risperidone	O
,	O
with	O
no	O
effect	O
on	O
psychopathology	B:C0004936
and	O
extrapyramidal	O
symptoms	I:C0234133
.	O

Adjunctive	O
aripiprazole	O
reduced	O
prolactin	O
levels	I:C0373706
in	O
those	O
treated	O
with	I:C0332293
risperidone	O
,	O
with	O
no	O
effect	O
on	O
psychopathology	O
and	O
extrapyramidal	B:C0234133
symptoms	I:C0234133
.	O

This	O
is	O
a	O
potential	O
treatment	B:C0087111
for	O
hyperprolactinaemia	O
observed	O
during	O
treatment	O
with	O
second	O
-	I:C0040615
generation	I:C0040615
antipsychotics	I:C0040615
.	O

This	O
is	O
a	O
potential	O
treatment	O
for	O
hyperprolactinaemia	B:C0020514
observed	O
during	O
treatment	O
with	O
second	O
-	I:C0040615
generation	I:C0040615
antipsychotics	I:C0040615
.	O

This	O
is	O
a	O
potential	O
treatment	O
for	O
hyperprolactinaemia	O
observed	O
during	O
treatment	B:C0087111
with	O
second	O
-	I:C0040615
generation	I:C0040615
antipsychotics	I:C0040615
.	O

This	O
is	O
a	O
potential	O
treatment	O
for	O
hyperprolactinaemia	O
observed	O
during	O
treatment	O
with	O
second	B:C0040615
-	I:C0040615
generation	I:C0040615
antipsychotics	I:C0040615
.	O

